BRPI0923514A2 - métodos e composição baseadas em pcv-2 para tratamento de porcos - Google Patents

métodos e composição baseadas em pcv-2 para tratamento de porcos

Info

Publication number
BRPI0923514A2
BRPI0923514A2 BRPI0923514A BRPI0923514A BRPI0923514A2 BR PI0923514 A2 BRPI0923514 A2 BR PI0923514A2 BR PI0923514 A BRPI0923514 A BR PI0923514A BR PI0923514 A BRPI0923514 A BR PI0923514A BR PI0923514 A2 BRPI0923514 A2 BR PI0923514A2
Authority
BR
Brazil
Prior art keywords
pcv
based methods
composition
pigs
compositions
Prior art date
Application number
BRPI0923514A
Other languages
English (en)
Inventor
G Sheppard Michael
T Lay Sui
Original Assignee
Vectogen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectogen Pty Ltd filed Critical Vectogen Pty Ltd
Publication of BRPI0923514A2 publication Critical patent/BRPI0923514A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos e composições baseadas em pcv-2 para tratamento de porcos a presente invenção está relacionada aos métodos e composições para a vacinação de porcos contra doenças associadas ao circovírus suíno tipo 2 (pcv-2). em particular, a invenção está relacionada aos vetores de expressão recombinantes que permitem a secreção ou expressão na membrana celular de uma forma truncada da proteína do quadro de leitura aberta 2 (orf2) de pcv-2.
BRPI0923514A 2008-12-15 2009-12-14 métodos e composição baseadas em pcv-2 para tratamento de porcos BRPI0923514A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12255508P 2008-12-15 2008-12-15
PCT/AU2009/001616 WO2010068969A1 (en) 2008-12-15 2009-12-14 Pcv 2-based methods and compositions for the treatment of pigs

Publications (1)

Publication Number Publication Date
BRPI0923514A2 true BRPI0923514A2 (pt) 2019-08-20

Family

ID=42240826

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923514A BRPI0923514A2 (pt) 2008-12-15 2009-12-14 métodos e composição baseadas em pcv-2 para tratamento de porcos

Country Status (14)

Country Link
US (1) US20100150959A1 (pt)
EP (1) EP2376639A1 (pt)
JP (1) JP2012511896A (pt)
KR (1) KR20110123725A (pt)
CN (1) CN102333876A (pt)
AR (1) AR074678A1 (pt)
AU (1) AU2009328622A1 (pt)
BR (1) BRPI0923514A2 (pt)
CA (1) CA2746340A1 (pt)
EA (1) EA201170813A1 (pt)
MX (1) MX2011006400A (pt)
SG (1) SG172183A1 (pt)
TW (1) TW201026850A (pt)
WO (1) WO2010068969A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
DK3127551T3 (da) 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101884787A (zh) * 2010-07-22 2010-11-17 洛阳普莱柯生物工程有限公司 猪圆环病毒2型亚单位疫苗及其制备方法
CN102827289B (zh) * 2012-08-30 2014-04-09 青岛蔚蓝生物股份有限公司 猪圆环病毒2型Cap蛋白和胸腺素α1融合蛋白及应用
CN102824634B (zh) * 2012-09-14 2014-03-19 范红结 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法
CN103920146A (zh) * 2013-01-14 2014-07-16 普莱柯生物工程股份有限公司 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用
EP2789346A1 (en) 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusion polypeptides and vaccines
WO2014187822A1 (en) * 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
CN104031925A (zh) * 2014-02-24 2014-09-10 福州大北农生物技术有限公司 优化的猪圆环病毒orf2基因的nls序列
CN104017813A (zh) * 2014-06-03 2014-09-03 斯澳生物科技（苏州）有限公司 截短的pcv2型衣壳蛋白orf2病毒样颗粒及其制备方法
US10767185B2 (en) * 2015-12-28 2020-09-08 Agricultural Technology Research Institute Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CN106399350B (zh) * 2016-09-07 2020-02-21 复旦大学 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
HUE064720T2 (hu) 2017-10-17 2024-04-28 Intervet Int Bv PCV2B ORF2 protein rekombináns expressziója rovarsejtekben
GB2574609A (en) * 2018-06-11 2019-12-18 Univ Cape Town Plant produced porcine circovirus pseudovirion
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
CN112834744A (zh) * 2020-12-31 2021-05-25 天津瑞普生物技术股份有限公司 一种猪群体内腺病毒3型中和抗体阳性率的elisa试剂盒及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
CN1769434A (zh) * 2005-08-30 2006-05-10 广东省农业科学院兽医研究所 一种猪圆环病毒2型重组腺病毒及其构建方法和应用
BRPI0714932A2 (pt) * 2006-07-28 2013-05-21 Commw Scient Ind Res Org mÉtodos e composiÇÕes para aumento do tropismo tecidual de vetores adenovirais recombinantes
CN101092631B (zh) * 2007-05-31 2010-04-14 华中农业大学 一种修饰的猪圆环病毒2型orf2基因及应用

Also Published As

Publication number Publication date
CN102333876A (zh) 2012-01-25
WO2010068969A1 (en) 2010-06-24
AU2009328622A1 (en) 2011-07-07
AR074678A1 (es) 2011-02-02
EA201170813A1 (ru) 2012-01-30
US20100150959A1 (en) 2010-06-17
MX2011006400A (es) 2011-09-15
KR20110123725A (ko) 2011-11-15
EP2376639A1 (en) 2011-10-19
TW201026850A (en) 2010-07-16
JP2012511896A (ja) 2012-05-31
SG172183A1 (en) 2011-07-28
CA2746340A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
BRPI0923514A2 (pt) métodos e composição baseadas em pcv-2 para tratamento de porcos
CL2008002611A1 (es) Uso de una composición inmunogénica que consiste de la proteína orf-2 de circovirus porcino tipo 2 (pcv-2) y uno o más vehículos aceptables en veterinaria, para preparar un medicamento útil para la reducción de infecciones concomitantes provocadas por pcv-2 y uno o más patógenos víricos, bacterianos y/o fúngicos diferentes de pcv-2 en cerdos.
GB0712160D0 (en) Methods and compositions in the treatment of procine circoviral infection
ECSP11011367A (es) Composición farmacéutica
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BRPI0923047B8 (pt) métodos para preparação de conjugados de proteínas- oligossacarídeos
BRPI0801858A2 (pt) uso de pelo menos um meio de cultura celular condicionado ou de seu extrato e composiÇço cosmÉtica ou dermatolàgica
BRPI0915813A2 (pt) estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos
EP3461507A8 (en) Cell-scaffold constructs
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
BRPI0608796B8 (pt) método para a preparação de um extrato de planta compreendendo bacuquiol
ES2622087T3 (es) Vacuna recombinante contra paramyxovirus aviar y procedimiento de fabricación y utilización de la misma
BRPI0809663A8 (pt) Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
ECSP11011297A (es) Proteinas ligadoras il-17
BR112019009133A2 (pt) vacina contra o parvovírus suíno
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BR112013017021A2 (pt) composição nutricional compreendendo fibra e probióticos para reduzir os sintomas intestinais realacionados ao estresse
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
BRPI0715360B8 (pt) método para a produção de uma proteína recombinante; método para a produção de uma proteína 2086 meningocócica recombinante (p2086); e composição
AR079526A1 (es) Vacuna multivalente contra los teschovirus porcinos y otros organismos que provocan enfermedades en los cerdos
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]